Last reviewed · How we verify

Mixed Gonococcal and Chlamydia Infection of the Cervix — Treatment Landscape & Competitive Intelligence

Mixed Gonococcal and Chlamydia Infection of the Cervix (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mixed Gonococcal and Chlamydia Infection of the Cervix, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Ofloxacine Ofloxacine Assistance Publique - Hôpitaux de Paris Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Mixed Gonococcal and Chlamydia Infection of the Cervix
  2. Assistance Publique - Hôpitaux de Paris · 1 drug in Mixed Gonococcal and Chlamydia Infection of the Cervix

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mixed Gonococcal and Chlamydia Infection of the Cervix:

Cite this brief

Drug Landscape (2026). Mixed Gonococcal and Chlamydia Infection of the Cervix — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mixed-gonococcal-and-chlamydia-infection-of-the-cervix. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing